Known symptomatic brain metastases (NOTE: patients with treated epidural disease are allowed)
Known central nervous system, meningeal, or epidural disease. However, subjects with known brain metastases are allowed if the brain metastases are stable for ? weeks before the first dose of study treatment.
Brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least  months before planned first dose of study drug
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least  weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment
Known primary mediastinal, ocular, epidural, testicular or breast DLBCL.
Known metastases in the brain or active epidural disease (NOTE: patients with treated epidural disease are allowed)
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least  weeks before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least  weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment.
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least  weeks before the first dose of study treatment; eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment
No known or suspected brain metastases (NOTE: patients with treated epidural disease are allowed)
Epidural analgesia
The subject has active brain metastases or epidural disease
Participants who have known central nervous system, meningeal, or epidural disease including brain metastases.
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least  weeks before the first dose of study treatment; eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment
Patients with circumferential epidural disease
RENAL COHORT: Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least  weeks before the first dose of study treatment; eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least  weeks before the first dose of study treatment; eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment
Brain metastases or active leptomeningeal disease (with the exception of participants with treated epidural disease and no other epidural progression)
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least  months before randomization.
Must have epidural metastasis to be treated with MRI-guided laser ablation
Patients with known central nervous system, meningeal, or epidural disease.
Patients with treated, non-progressive epidural disease are eligible
Patients with treated, non-progressive epidural disease are eligible
No known or suspected brain metastases (NOTE: patients with treated epidural disease are allowed)
Known symptomatic or uncontrolled brain metastases or epidural disease
Known brain metastases or cranial epidural disease unless adequately treated and stable for at least  weeks before first dose of study treatment.
Patients with known central nervous system, meningeal, or epidural disease. Patients with stable brain metastases following definitive local treatment are eligible if steroid requirement is < mg/day of prednisone (or equivalent).
Known brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least  months)
Active use of an epidural catheter
Known central nervous system, meningeal or epidural disease including brain metastases
Metastases in the brain or active epidural disease. (Note: patients with treated epidural disease are allowed);
Technical contraindications to epidural placement: previous thoracic spinal surgery or local skin or soft tissue infection at proposed site for epidural insertion
All patients must have a thoracic epidural placed pre-operatively for perioperative analgesia; epidural will be loaded with  mg of duramorph after induction of anesthesia and will be started at a rate of  ml/hr upon the conclusion of the surgery; a solution of . % bupivacaine with  mcg/ml epinephrine will be used for analgesia; epidural rate will be adjusted for optimal coverage and stable hemodynamics
Patients must be eligible for epidural placement
Patients with epidural compression are eligible provided that there is a >=  mm gap between the spinal cord and the edge of the epidural lesion
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least  months before study enrollment; eligible subjects must be without corticosteroid treatment at the time of study enrollment
Technical contraindications to epidural placement: previous thoracic spinal surgery or local skin or soft tissue infection at proposed site for epidural insertion